학술논문

Recommendations on data sharing in HIV drug resistance research
Document Type
article
Source
PLOS Medicine. 20(9)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Antimicrobial Resistance
Sexually Transmitted Infections
Infectious Diseases
HIV/AIDS
5.1 Pharmaceuticals
6.1 Pharmaceuticals
Infection
Good Health and Well Being
Humans
HIV Infections
Phylogeny
HIV-1
Drug Resistance
Viral
Anti-Retroviral Agents
Mutation
Anti-HIV Agents
Medical and Health Sciences
General & Internal Medicine
Biomedical and clinical sciences
Health sciences
Language
Abstract
• Human immunodeficiency virus (HIV) drug resistance has implications for antiretroviral treatment strategies and for containing the HIV pandemic because the development of HIV drug resistance leads to the requirement for antiretroviral drugs that may be less effective, less well-tolerated, and more expensive than those used in first-line regimens.  • HIV drug resistance studies are designed to determine which HIV mutations are selected by antiretroviral drugs and, in turn, how these mutations affect antiretroviral drug susceptibility and response to future antiretroviral treatment regimens.  • Such studies collectively form a vital knowledge base essential for monitoring global HIV drug resistance trends, interpreting HIV genotypic tests, and updating HIV treatment guidelines.  • Although HIV drug resistance data are collected in many studies, such data are often not publicly shared, prompting the need to recommend best practices to encourage and standardize HIV drug resistance data sharing.  • In contrast to other viruses, sharing HIV sequences from phylogenetic studies of transmission dynamics requires additional precautions as HIV transmission is criminalized in many countries and regions.  • Our recommendations are designed to ensure that the data that contribute to HIV drug resistance knowledge will be available without undue hardship to those publishing HIV drug resistance studies and without risk to people living with HIV.